Spil Drug Patent Portfolio
Spil owns 2 orange book drugs protected by 4 US patents Given below is the list of Spil's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10898444 | Extended release multiparticulates of ranolazine | 24 Jan, 2038 | Active |
| US11510878 | Extended release multiparticulates of ranolazine | 24 Jan, 2038 | Active |
| US9504655 | Capsule dosage form of metoprolol succinate | 09 Jul, 2035 | Active |
| US9700530 | Capsule dosage form of metoprolol succinate | 09 Jul, 2035 | Active |
Latest Legal Activities on Spil's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Spil.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 29 May, 2024 | US9504655 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 29 Nov, 2022 | US11510878 |
|
Recordation of Patent Grant Mailed
Critical
| 29 Nov, 2022 | US11510878 |
|
Email Notification
Critical
| 10 Nov, 2022 | US11510878 |
|
Issue Notification Mailed
Critical
| 09 Nov, 2022 | US11510878 |
|
Application Is Considered Ready for Issue
Critical
| 28 Oct, 2022 | US11510878 |
| Dispatch to FDC | 28 Oct, 2022 | US11510878 |
|
Issue Fee Payment Verified
Critical
| 25 Oct, 2022 | US11510878 |
|
Issue Fee Payment Received
Critical
| 25 Oct, 2022 | US11510878 |
|
Email Notification
Critical
| 07 Oct, 2022 | US11510878 |
|
Mail Notice of Allowance
Critical
| 07 Oct, 2022 | US11510878 |
|
Electronic Review
Critical
| 07 Oct, 2022 | US11510878 |
|
Notice of Allowance Data Verification Completed
Critical
| 05 Oct, 2022 | US11510878 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 27 Sep, 2022 | US11510878 |
|
Email Notification
Critical
| 27 Sep, 2022 | US11510878 |
Spil's Family Patents
Spil Drug List
Given below is the complete list of Spil's drugs and the patents protecting them.
1. Aspruzyo Sprinkle
Aspruzyo Sprinkle is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10898444 | Extended release multiparticulates of ranolazine |
24 Jan, 2038
(13 years from now)
| Active |
| US11510878 | Extended release multiparticulates of ranolazine |
24 Jan, 2038
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aspruzyo Sprinkle's drug page
2. Kapspargo Sprinkle
Kapspargo Sprinkle is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9504655 | Capsule dosage form of metoprolol succinate |
09 Jul, 2035
(10 years from now)
| Active |
| US9700530 | Capsule dosage form of metoprolol succinate |
09 Jul, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kapspargo Sprinkle's drug page